feinstein, northwell
Northwell Health's Feinstein Institutes for Medical Research is beginning three studies alongside Sanofi, Gilead Sciences and Regeneron Pharmaceuticals. These studies will test possible treatments for moderate and severe cases of COVID-19. (Photo via Northwell Health)

Northwell Health’s Feinstein Institutes Teams Up with Sanofi, Regeneron Pharmaceuticals, Gilead Sciences to Test COVID-19 Treatments

The research arm of Northwell Health (No. 2 on DiversityInc’s 2019 Top Hospitals & Health Systems), the Feinstein Institutes for Medical Research, is partnering with Gilead Sciences, Regeneron Pharmaceuticals and Sanofi (No. 31 on DiversityInc’s 2019 Top 50 Companies for Diversity) to identify treatments for people hospitalized with moderate to severe cases of the novel coronavirus (COVID-19).

The Feinstein Institutes announced last week the enrollment of three clinical trials aimed at finding an effective treatment for those diagnosed with the coronavirus. Due to the urgency of the issue, there has been a nationwide push for expedited Food and Drug Administration (FDA) approvals of experimental COVID-19 therapies. However, Northwell Health and the Feinstein Institutes announced the trials would continue through the typical, lengthier process to ensure accuracy.

Two of the trials, which will be conducted with Gilead, will involve the drug remdesivir. Remdesivir is an antiviral drug that is designed to reduce the length and intensity of a COVID-19 infection. Northwell Health said the drug had shown promise in working against similar viruses like MERS and SARS in test tubes and animal models. The first trial has room for 400 subjects with severe cases of COVID-19 worldwide. Researchers will administer the drug intravenously in two different durations and measure patients’ bodies’ responses. Feinstein Institutes’ Marcia Epstein, MD, an infectious disease expert, will lead this study.

The other Gilead remdesivir trial will assess two different durations of treatment with the drug and compare it to the current treatment methods in up to 600 patients with moderate cases of COVID-19. Researchers will also look at improvement of symptoms and time of discharge. Prashant Malhotra, MD, will lead this study. Malhotra is an assistant professor of the Institute of Health Innovations & Outcomes Research at Feinstein Institutes and is an infectious disease expert.

In the third study, Feinstein will collaborate with Regeneron and Sanofi. The trial will look at approximately 400 severe or critical cases of COVID-19 in hospitals across the U.S. This trial will study the efficacy of a human antibody called sarilumab that may help prevent complications connected to severe pneumonia in COVID-19 patients. This study adds to a preliminary Chinese trial that found the use of the antibody helped reduce fever in all patients.

China has approved its use to treat patients with severe or critical cases. Negin Hajizadeh, MD, an assistant professor in the Institute of Health Innovations & Outcomes Research and a pulmonary critical care doctor will be leading this study.

To read more about these studies and Northwell’s plans to combat COVID-19, visit northwell.edu.

Latest News

ADP Appoints Nazzic S. Keene to Board of Directors

Originally posted on ADP.com ADP, a leading global technology company providing human capital management (HCM) solutions, announced today that Nazzic S. Keene has been appointed to the Board of Directors, effective April 8, 2020. Ms. Keene is a well-respected industry leader with three decades of experience in information systems and technology services, and more than…

Kaiser Permanente Mental Health App Now Available to Members at No Cost

Originally published on about.kaiserpermanente.org.  myStrength app is part of Kaiser Permanente’s effort to provide valuable tools to support mental and emotional health, particularly during stressful times. As part of its commitment to offer members innovative ways to promote personal health and wellness, particularly during increasing levels of stress and anxiety,…

AT&T Believing in our COVID-19 First Responders

Originally posted on ATT.com AT&T supports first responders, medical personnel, responding to COVID-19 with nourishing meals  Across the country – and around the world – first responders and medical personnel are playing a critical role in helping care for their communities during the COVID-19 crisis. “First responders and medical personnel…

Humana Announces Health Care Provider Initiative to Help Ease Financial and Administrative Stress During Coronavirus Pandemic

Originally posted on Humana.com Leading health and well-being company Humana Inc., announced actions designed to help provide financial and administrative relief for the health care provider community facing unprecedented strain during the coronavirus pandemic. First, Humana is implementing simplified and expedited claims processing, in order to get reimbursement payments to providers…